CBUS trades 704.2% below Wall Street's consensus target of $11.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CBUS achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 30, 2026, Cibus, Inc. (CBUS) has a Wall Street consensus price target of $11.50, based on estimates from 4 covering analysts. With the stock currently trading at $1.43, this represents a potential upside of +704.2%. The company has a market capitalization of $932M.
Analyst price targets range from a low of $10.50 to a high of $12.50, representing a 17% spread in expectations. The median target of $11.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CBUS trades at a trailing P/E of -0.5x. Analysts expect EPS to grow -683.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
PGENPrecigen, Inc. | $1.8B | $5.92 | $14.00 | +136.5% | Buy | — | 16 |
RKDAArcadia Biosciences, Inc. | $1M | $0.70 | — | — | — | — | — |
SEEDOrigin Agritech Limited | $8M | $1.05 | — | — | — | — | — |
APLDApplied Digital Corporation | $10.8B | $37.77 | $76.63 | +102.9% | Buy | — | 13 |
OFIXOrthofix Medical Inc. | $391M | $9.68 | $15.60 | +61.2% | Hold | — | 17 |
CTVACorteva, Inc. | $56.0B | $83.37 | $89.13 | +6.9% | Buy | 22.3x | 37 |
FMCFMC Corporation | $1.4B | $11.54 | $16.10 | +39.5% | Hold | 6.7x | 42 |
BIOXBioceres Crop Solutions Corp. | $21M | $0.33 | — | — | — | — | — |
AMTXAemetis, Inc. | $115M | $1.69 | $1.75 | +3.6% | Buy | — | 7 |
DEDeere & Company | $169.2B | $626.63 | $690.00 | +10.1% | Hold | 34.7x | 46 |
Quick answers to the most common questions about buying CBUS stock.
The consensus Wall Street price target for CBUS is $11.5, representing 704.2% upside from the current price of $1.43. With 4 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CBUS has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $11.5 implies 704.2% upside from current levels.
CBUS's current price is $1.43 with a consensus target of $11.5 (704.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $12.5 for CBUS, while the most conservative target is $10.5. The consensus of $11.5 represents the median expectation. These targets typically reflect 12-month expectations.
CBUS is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CBUS stock forecast based on 4 Wall Street analysts shows a consensus price target of $11.5, with estimates ranging from $10.5 (bear case) to $12.5 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on CBUS, with a "Buy" consensus rating and $11.5 price target (704.2% upside). 3 of 4 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CBUS analyst price targets range from $10.5 to $12.5, a 17% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $11.5 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.